Please enable JavaScript to continue using this application.

Compare $CRVS vs $RIGL | Chartloom

Compare

$CRVS vs $RIGL

Corvus Pharmaceuticals Inc · Rigel Pharmaceuticals Inc

CRVS

Corvus Pharmaceuticals Inc

RIGL

Rigel Pharmaceuticals Inc

Compare $CRVS vs $RIGL

Comparing Corvus Pharmaceuticals Inc and Rigel Pharmaceuticals Inc

CRVSCorvus Pharmaceuticals Inc

RIGLRigel Pharmaceuticals Inc

CRVSCorvus Pharmaceuticals Inc

Market cap

$885M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

43.7%

52W performance

50.3%

FCF yield

-5.1%

RIGLRigel Pharmaceuticals Inc

Market cap

$908M

P/E (TTM)

2.98x

Forward P/E (NTM)

15.85x

Forward P/S (NTM)

2.61x

Rev growth (TTM)

3.3%

YTD performance

17.3%

52W performance

70.7%

FCF yield

1.0%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

CRVS

RIGL

Detailed metrics comparison

CRVS

Corvus Pharmaceuticals Inc

RIGL

Rigel Pharmaceuticals Inc

Market Cap

CRVS$885M

RIGL$908M

Enterprise Value

CRVS$866M

RIGL$886M

Price

CRVS$10.52

RIGL$49.08

P/E Ratio

CRVSN/A

RIGL2.98x

P/S Ratio

CRVS0.00x

RIGL3.28x

EV/Sales

CRVS0.00x

RIGL3.20x

EV/EBITDA

CRVS0.00x

RIGL9.50x

P/B Ratio

CRVS4.07x

RIGL2.07x

P/FCF Ratio

CRVSN/A

RIGL100.69x

EV/FCF

CRVS-19.14x

RIGL98.29x

PEG Ratio

CRVSN/A

RIGL0.01x

Forward P/E (NTM)

CRVSN/A

RIGL15.85x

Forward P/S (NTM)

CRVSN/A

RIGL2.61x

Revenue (TTM)

CRVS$0

RIGL$277M

Revenue Growth (YoY)

CRVSN/A

RIGL3.3%

Forward Rev Growth

CRVS1220.6%

RIGL21.9%

Gross Margin (TTM)

CRVS0.0%

RIGL91.4%

Operating Margin (TTM)

CRVS0.0%

RIGL31.4%

EBITDA Margin (TTM)

CRVS0.0%

RIGL32.4%

Net Margin (TTM)

CRVS0.0%

RIGL116.3%

FCF Margin (TTM)

CRVSN/A

RIGL3.3%

Net Income (TTM)

CRVS$-54M

RIGL$322M

FCF (TTM)

CRVS$-45M

RIGL$9M

EPS (TTM)

CRVS-$0.59

RIGL$16.45

ROE (TTM)

CRVS-3615.0%

RIGL96.5%

ROA (TTM)

CRVS-3362.0%

RIGL72.3%

ROIC (TTM)

CRVS-3615.0%

RIGL84.1%

Cash

CRVS$19M

RIGL$61M

Debt

CRVS$0

RIGL$39M

Net Cash/Debt

CRVS$19M

RIGL$22M

Current Ratio (TTM)

CRVS16.16x

RIGL1.94x

Quick Ratio (TTM)

CRVS15.92x

RIGL1.58x

Debt/Equity (TTM)

CRVS0.00x

RIGL0.09x

Debt/Assets (TTM)

CRVS0.0%

RIGL0.0%

Interest Coverage (TTM)

CRVSN/A

RIGLN/A

Net Debt/EBITDA (TTM)

CRVS0.00x

RIGL0.00x

Beta

CRVS1.59

RIGL1.26

52W Performance

CRVS50.3%

RIGL70.7%

YTD Performance

CRVS43.7%

RIGL17.3%

% from 52W High

CRVS-61.0%

RIGL-6.0%

% from 52W Low

CRVS64.6%

RIGL96.7%

Asset Turnover (TTM)

CRVS0.00x

RIGL0.62x

FCF Yield (TTM)

CRVS-5.1%

RIGL1.0%

Earnings Yield (TTM)

CRVS-6.1%

RIGL35.5%

Dividend Yield (TTM)

CRVSN/A

RIGLN/A

Rule of 40

CRVS0.0

RIGL6.6

EV/GP/RG

CRVSN/A

RIGL0.13

Ticker research

View CRVS research View RIGL research

Metric	CRVS Corvus Pharmaceuticals Inc	RIGL Rigel Pharmaceuticals Inc
Market & Valuation
Market Cap	$885M	$908M
Enterprise Value	$866M	$886M
Price	$10.52	$49.08
P/E Ratio	N/A	2.98x
P/S Ratio	0.00x	3.28x
EV/Sales	0.00x	3.20x
EV/EBITDA	0.00x	9.50x
P/B Ratio	4.07x	2.07x
P/FCF Ratio	N/A	100.69x
EV/FCF	-19.14x	98.29x
PEG Ratio	N/A	0.01x
Forward P/E (NTM)	N/A	15.85x
Forward P/S (NTM)	N/A	2.61x
Revenue & Growth
Revenue (TTM)	$0	$277M
Revenue Growth (YoY)	N/A	3.3%
Forward Rev Growth	1220.6%	21.9%
Profitability
Gross Margin (TTM)	0.0%	91.4%
Operating Margin (TTM)	0.0%	31.4%
EBITDA Margin (TTM)	0.0%	32.4%
Net Margin (TTM)	0.0%	116.3%
FCF Margin (TTM)	N/A	3.3%
Net Income (TTM)	$-54M	$322M
FCF (TTM)	$-45M	$9M
EPS (TTM)	-$0.59	$16.45
ROE (TTM)	-3615.0%	96.5%
ROA (TTM)	-3362.0%	72.3%
ROIC (TTM)	-3615.0%	84.1%
Financial Health
Cash	$19M	$61M
Debt	$0	$39M
Net Cash/Debt	$19M	$22M
Current Ratio (TTM)	16.16x	1.94x
Quick Ratio (TTM)	15.92x	1.58x
Debt/Equity (TTM)	0.00x	0.09x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.59	1.26
52W Performance	50.3%	70.7%
YTD Performance	43.7%	17.3%
% from 52W High	-61.0%	-6.0%
% from 52W Low	64.6%	96.7%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.62x
FCF Yield (TTM)	-5.1%	1.0%
Earnings Yield (TTM)	-6.1%	35.5%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	6.6
EV/GP/RG	N/A	0.13
Ticker research	View CRVS research	View RIGL research

Valuation

P/E Ratio

RIGL

2.98x

P/S Ratio

CRVS

0.00x

RIGL

3.28x

EV/FCF

CRVS

-19.14x

RIGL

98.29x

Growth & revenue

Revenue Growth TTM

RIGL

3.3%

Forward Revenue Growth

CRVS

1220.6%

RIGL

21.9%

Profitability & performance

Gross Margin

RIGL

91.4%

CRVS

0.0%

ROE

RIGL

96.5%

CRVS

-3615.0%

FCF Yield %

RIGL

1.0%

CRVS

-5.1%

52-Week Performance

RIGL

70.7%

CRVS

50.3%

Detailed metrics comparison

CRVS

Corvus Pharmaceuticals Inc

RIGL

Rigel Pharmaceuticals Inc

Market Cap

CRVS$885M

RIGL$908M

Enterprise Value

CRVS$866M

RIGL$886M

Price

CRVS$10.52

RIGL$49.08

P/E Ratio

CRVSN/A

RIGL2.98x

P/S Ratio

CRVS0.00x

RIGL3.28x

EV/Sales

CRVS0.00x

RIGL3.20x

EV/EBITDA

CRVS0.00x

RIGL9.50x

P/B Ratio

CRVS4.07x

RIGL2.07x

P/FCF Ratio

CRVSN/A

RIGL100.69x

EV/FCF

CRVS-19.14x

RIGL98.29x

PEG Ratio

CRVSN/A

RIGL0.01x

Forward P/E (NTM)

CRVSN/A

RIGL15.85x

Forward P/S (NTM)

CRVSN/A

RIGL2.61x

Revenue (TTM)

CRVS$0

RIGL$277M

Revenue Growth (YoY)

CRVSN/A

RIGL3.3%

Forward Rev Growth

CRVS1220.6%

RIGL21.9%

Gross Margin (TTM)

CRVS0.0%

RIGL91.4%

Operating Margin (TTM)

CRVS0.0%

RIGL31.4%

EBITDA Margin (TTM)

CRVS0.0%

RIGL32.4%

Net Margin (TTM)

CRVS0.0%

RIGL116.3%

FCF Margin (TTM)

CRVSN/A

RIGL3.3%

Net Income (TTM)

CRVS$-54M

RIGL$322M

FCF (TTM)

CRVS$-45M

RIGL$9M

EPS (TTM)

CRVS-$0.59

RIGL$16.45

ROE (TTM)

CRVS-3615.0%

RIGL96.5%

ROA (TTM)

CRVS-3362.0%

RIGL72.3%

ROIC (TTM)

CRVS-3615.0%

RIGL84.1%

Cash

CRVS$19M

RIGL$61M

Debt

CRVS$0

RIGL$39M

Net Cash/Debt

CRVS$19M

RIGL$22M

Current Ratio (TTM)

CRVS16.16x

RIGL1.94x

Quick Ratio (TTM)

CRVS15.92x

RIGL1.58x

Debt/Equity (TTM)

CRVS0.00x

RIGL0.09x

Debt/Assets (TTM)

CRVS0.0%

RIGL0.0%

Interest Coverage (TTM)

CRVSN/A

RIGLN/A

Net Debt/EBITDA (TTM)

CRVS0.00x

RIGL0.00x

Beta

CRVS1.59

RIGL1.26

52W Performance

CRVS50.3%

RIGL70.7%

YTD Performance

CRVS43.7%

RIGL17.3%

% from 52W High

CRVS-61.0%

RIGL-6.0%

% from 52W Low

CRVS64.6%

RIGL96.7%

Asset Turnover (TTM)

CRVS0.00x

RIGL0.62x

FCF Yield (TTM)

CRVS-5.1%

RIGL1.0%

Earnings Yield (TTM)

CRVS-6.1%

RIGL35.5%

Dividend Yield (TTM)

CRVSN/A

RIGLN/A

Rule of 40

CRVS0.0

RIGL6.6

EV/GP/RG

CRVSN/A

RIGL0.13

Ticker research

View CRVS research View RIGL research

Metric	CRVS Corvus Pharmaceuticals Inc	RIGL Rigel Pharmaceuticals Inc
Market & Valuation
Market Cap	$885M	$908M
Enterprise Value	$866M	$886M
Price	$10.52	$49.08
P/E Ratio	N/A	2.98x
P/S Ratio	0.00x	3.28x
EV/Sales	0.00x	3.20x
EV/EBITDA	0.00x	9.50x
P/B Ratio	4.07x	2.07x
P/FCF Ratio	N/A	100.69x
EV/FCF	-19.14x	98.29x
PEG Ratio	N/A	0.01x
Forward P/E (NTM)	N/A	15.85x
Forward P/S (NTM)	N/A	2.61x
Revenue & Growth
Revenue (TTM)	$0	$277M
Revenue Growth (YoY)	N/A	3.3%
Forward Rev Growth	1220.6%	21.9%
Profitability
Gross Margin (TTM)	0.0%	91.4%
Operating Margin (TTM)	0.0%	31.4%
EBITDA Margin (TTM)	0.0%	32.4%
Net Margin (TTM)	0.0%	116.3%
FCF Margin (TTM)	N/A	3.3%
Net Income (TTM)	$-54M	$322M
FCF (TTM)	$-45M	$9M
EPS (TTM)	-$0.59	$16.45
ROE (TTM)	-3615.0%	96.5%
ROA (TTM)	-3362.0%	72.3%
ROIC (TTM)	-3615.0%	84.1%
Financial Health
Cash	$19M	$61M
Debt	$0	$39M
Net Cash/Debt	$19M	$22M
Current Ratio (TTM)	16.16x	1.94x
Quick Ratio (TTM)	15.92x	1.58x
Debt/Equity (TTM)	0.00x	0.09x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.59	1.26
52W Performance	50.3%	70.7%
YTD Performance	43.7%	17.3%
% from 52W High	-61.0%	-6.0%
% from 52W Low	64.6%	96.7%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.62x
FCF Yield (TTM)	-5.1%	1.0%
Earnings Yield (TTM)	-6.1%	35.5%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	6.6
EV/GP/RG	N/A	0.13
Ticker research	View CRVS research	View RIGL research